Abstract

Leukaemia is among the leading haematological disorders causing the deaths of many in the society. This paper was reviewed to update the dangers associated with acute leukaemia. The paper was reviewed using different search engines like Google scholar, Researchgate, Pubmed, Scopus, etc. Acute leukaemia is a leukaemia with serious medical conditions needing emergency medical attention. It can convert sometimes to chronic leukaemia. The onset of the course of the disease is sudden and life-threatening. Prompt diagnosis could be helpful in the management of the patients. The experts involved in the diagnosis and management should attend regular trainings and conferences to update themselves on the new approaches on acute leukaemia to achieve optimal results in the patients. This paper tried to update the public on the overview, course, mechanism, treatment and diagnosis of acute leukaemia.

Keywords: Acute Leukaemia; Acute Myeloid Leukaemia; Acute Lymphoblastic Leukaemia; Myelogenous Leukaemia

References

1. Wolach O and Stone RM. “How I treat mixed-phenotype acute leukemia”. Blood 125.16 (2015): 2477-2485. 
2. “Adult Acute Myeloid Leukemia Treatment”. National Cancer Institute (2017). 
3. Marino Bradley S and Fine Katie S. “Blueprints Pediatrics”. Lippincott Williams and Wilkins (2013): 205. 
4. Döhner H., et al. “Acute Myeloid Leukemia”. The New England Journal of Medicine 373.12 (2015): 1136-1152. 
5. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015”. Lancet 388.10053 (2016): 1545-1602.
6. Hoffman R. “Hematology: Basic Principles and Practice (4^th edition.)”. St. Louis, Mo.: Elsevier Churchill Livingstone (2005): 1074-1075. 
7. Abeloff and Martin. “Clinical Oncology (3^rd edition.)”. St. Louis, Mo.: Elsevier Churchill Livingstone (2004): 2834. 
8. Jaiswal Siddhartha., et al. “Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes”. New England Journal of Medicine 371.26 (2014): 2488-2498.
9. Thirman MJ., et al. “Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations”. The New England Journal of Medicine 329.13 (1993): 909-914.
10. Linet MS. “The Leukemias: Epidemiologic Aspects”. Oxford University Press, New York (1985).
11. Yoshinaga S., et al. “Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies”. Radiology 233.2 (2004): 313-321.
12. Radivoyevitch T., et al. “Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation". Leukemia 30.2 (2016): 285-294. 
13. Horwitz M. “The genetics of familial leukemia”. Leukemia 11.8 (1997): 1347-1359. 
14. Crispino JD and Horwitz MS. “GATA factor mutations in hematologic disease”. Blood 129.15 (2017): 2103-2110.
15. Fialkow PJ., et al. “Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy”. Blood 77.7 (1991): 1415-1417.
16. Bonnet D and Dick JE. "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell". Nature Medicine 3.7 (1997): 730-737. 
17. Greer JP., et al. “Wintrobe's Clinical Hematology (11^th edition.)”. Philadelphia: Lippincott, Williams, and Wilkins (2004): 2045-2062. 
18. Molenaar Remco J., et al. “The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846.2 (2014): 326-341. 
19. Kayser S and Levis MJ. “FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations”. Leukemia and Lymphoma 55.2 (2014): 243-255. 
20. Fenaux P., et al. “A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. The European APL Group”. Blood 94.4 (1999): 1192-1200. 
21. Estey EH. “Treatment of acute myelogenous leukemia”. Oncology 16.3 (2002): 343-356. 
22. Appelbaum FR., et al. “NCCN Practice Guidelines for Acute Myelogenous Leukemia". Oncology 14.11 (2000): 53-61.
23. Brune M., et al. “Improved leukemia-free survival after post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial". Blood 108.1 (2006): 88-96.
24. Hunger Stephen P and Mullighan Charles G. “Acute Lymphoblastic Leukemia in Children”. New England Journal of Medicine 373.16 (2015): 1541-1552. 
25. Inaba H., et al. “Acute lymphoblastic leukaemia". Lancet 381.991 (2013): 1943-1955. 
26. Ferri Fred F. “Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1”. Elsevier Health Sciences (2017): 743. 
27. Paul Shilpa., et al. “Adult Acute Lymphoblastic Leukemia". Mayo Clinic Proceedings 91.11 (2016): 1645-1666. 
28. Besa EC., et al. “Chronic Myelogenous Leukemia". Medscape Reference. Web MD (2013).
29. Provan D and Gribben JG. “Chapter 7 Chronic myelogenous leukemia. Molecular Hematology (3^rd edition)”. Singapore: Wiley-Blackwell (2010).
30. Tefferi A., et al. “Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel”. Blood 110.4 (2007): 1092-1097.
31. Weick JK., et al. “A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study”. Blood 88.8 (1996): 2841-2851.